 As a result of these facts, the current project was designed to develop a prototype longitudinal biomarker e.g., blood based proteins and biometric e.g., imaging or wearable wireless device monitoring strategy for carriers of the TP53 mutation with an even more pronounced predisposition to cancer due to familial aggregation of cancer. This monitoring strategy could be useful in identifying changes in those biomarkers that might either reflect cancer formation or health-related phenomena that may exacerbate susceptibility to cancer. The project will leverage different markers, assays and devices, as well the development of an analysis and prototype visualization method for drawing inferences from the marker and device data. Ultimately, the protocol will be focused on the objective, statistical evidence-based assessment of the utility of biomarker-based surveillance methods for an individual subject carrying a TP53 mutation in a high-cancer susceptibility setting e.g., a sibling with Li-Fraumeni syndrome and familial cancers in older generations. The protocol will include the vetted markers described by Villani et al.1 as well as a more comprehensive set of markers, biometrics and procedures in order to increase the likelihood of detecting values or changes in the status of these markers of likely biomedical importance. Since over 50 47 of the cancer survivors successfully monitored in the Villani et al. 2011 study were under age 20, the fact that the age-of-onset of cancer among TP53 mutation carriers is lowest for those with a family history of Li-Fraumeni and early onset cancers, and the published reports state age-of-onset of cancer among TP53 mutation carriers is so low e.g., Table 1, we believe that deploying this protocol in minors and children is justified. Since many of the biomarkers to be studied are likely to have a genetic basis, it makes sense to collect phenotypes and biosamples from family members of the target patient so that their values can act as control values for the target patients values. 